Audentes Therapeutics (BOLD) Stock Rating Upgraded by ValuEngine

Share on StockTwits

Audentes Therapeutics (NASDAQ:BOLD) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a report issued on Friday.

Several other brokerages have also weighed in on BOLD. Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a report on Friday, May 11th. BidaskClub downgraded shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 15th. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Mizuho began coverage on shares of Audentes Therapeutics in a research report on Monday, February 12th. They set a “neutral” rating and a $26.00 target price for the company. Finally, HC Wainwright set a $37.00 target price on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Audentes Therapeutics currently has an average rating of “Buy” and a consensus price target of $37.22.

Shares of NASDAQ BOLD traded down $0.14 during trading on Friday, hitting $37.76. 219,431 shares of the company traded hands, compared to its average volume of 442,396. Audentes Therapeutics has a fifty-two week low of $14.06 and a fifty-two week high of $42.61. The firm has a market capitalization of $1.36 billion, a P/E ratio of -11.11 and a beta of 1.22.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.07. sell-side analysts forecast that Audentes Therapeutics will post -3.31 earnings per share for the current fiscal year.

In other news, VP Suyash Prasad sold 1,900 shares of the stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $30.00, for a total transaction of $57,000.00. Following the completion of the transaction, the vice president now directly owns 1,900 shares of the company’s stock, valued at approximately $57,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew R. Patterson sold 20,300 shares of the stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $38.15, for a total transaction of $774,445.00. Following the transaction, the chief executive officer now directly owns 13,600 shares of the company’s stock, valued at $518,840. The disclosure for this sale can be found here. Insiders sold a total of 736,769 shares of company stock valued at $25,447,459 over the last ninety days. 6.60% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the stock. Tortoise Investment Management LLC purchased a new stake in shares of Audentes Therapeutics during the 1st quarter valued at approximately $112,000. Teacher Retirement System of Texas purchased a new stake in Audentes Therapeutics in the 4th quarter worth approximately $208,000. Cubist Systematic Strategies LLC purchased a new stake in Audentes Therapeutics in the 1st quarter worth approximately $204,000. MetLife Investment Advisors LLC purchased a new stake in Audentes Therapeutics in the 4th quarter worth approximately $248,000. Finally, California Public Employees Retirement System purchased a new stake in Audentes Therapeutics in the 1st quarter worth approximately $322,000. Institutional investors own 95.29% of the company’s stock.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Columbus McKinnon Corp.  Receives $49.67 Average Price Target from Brokerages
Columbus McKinnon Corp. Receives $49.67 Average Price Target from Brokerages
Silgan Holdings Inc.  Given Average Recommendation of “Hold” by Brokerages
Silgan Holdings Inc. Given Average Recommendation of “Hold” by Brokerages
Tracto  1-Day Volume Hits $630.00
Tracto 1-Day Volume Hits $630.00
Version Tops 1-Day Volume of $47.00
Version Tops 1-Day Volume of $47.00
EVO Payments  Sets New 1-Year High at $23.76
EVO Payments Sets New 1-Year High at $23.76
USA Technologies  Sets New 52-Week High at $15.15
USA Technologies Sets New 52-Week High at $15.15


© 2006-2018 Ticker Report. Google+.